Huperzine A for Managing and Treating Dementia
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Dementia is a progressive brain disorder. It is currently being treated with acetylcholinesterase inhibitors (AChEIs), which offer symptomatic relief but often cause adverse effects and do not modify disease progression. This chapter examines Huperzine A ( HupA ), a natural alkaloid from Huperzia serrata , as a potential therapeutic agent. HupA is a potent, selective, and reversible AChEI, and its bioavailability and blood–brain barrier penetration are higher than those of standard drugs. Beyond its cholinergic action, it exhibits multi-target neuroprotective effects, including anti-apoptotic, antioxidant, and antiamyloid properties. Evidence from clinical studies shows that HupA offers cognitive improvements in patients with Alzheimer's disease and vascular dementia with a favorable safety profile. However, study quality, regulatory status, and sustainable sourcing challenges remain. Future directions require large-scale, long-term trials and advanced delivery systems to fully integrate HupA into mainstream dementia therapy.
Fields of Study & Subjects
Cholinesterase and Neurodegenerative Diseases
Alzheimer's disease research and treatments
Medicinal Plants and Neuroprotection
Publication details
- Journal / source
- CRC Press eBooks
- Pages
- 58–69
- Publication date
- 31 March 2026
- Language
- EN
- Document type
- Book chapter